Interestingly, miR-29b oligonucleotides as well as pharmacological re-activation of miR-29b via HDAC-inhibition, exert anti-AML activity in KIT-driven AMLs, therefore providing a novel experimental platform to treat this specific AML clinical subgroup [43]. Here, HDAC9 is linked to acute myeloid leukemia.